Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD—A Cost-Effectiveness Analysis in the Czech Republic

ConclusionsFrom the perspective of the Czech health care system, managing COPD using IND/GLY is cost-effective in this analysis because the base-case is clearly below the willingness-to-pay threshold in the Czech Republic, which is automatically set at 3 times GDP/capita (approximately ζ44,000/ QALY). This is the first available economic analysis utilizing FLAME study results in the Central East European (CEE) countries showing IND/ GLY as a highly cost-effective investment into COPD patients.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research